Main Uses of Z-HYALCOAT

Z-HYALCOAT is a sterile, viscoelastic solution used as a surgical aid during procedures involving the anterior segment of the human eye. Its primary application is to maintain the integrity of the ocular spaces and protect sensitive internal structures during delicate surgical maneuvers.

Common procedures where Z-HYALCOAT is utilized include:

• Cataract Extraction: Assisting in the removal of the clouded lens.
• Intraocular Lens (IOL) Implantation: Facilitating the placement of artificial lens replacements.
• Corneal Transplant Surgery: Helping to manage the surgical site during keratoplasty.
• Glaucoma Surgery: Maintaining the anterior chamber depth during filtration procedures.

Benefits in Ophthalmic Surgery

Z-HYALCOAT provides several functional benefits that contribute to the success of ophthalmic operations:

Space Maintenance

The solution has specific rheological properties that allow it to create and maintain a deep anterior chamber. This provides the surgeon with a clear, stable field of view and sufficient room to manipulate surgical instruments safely.

Tissue Protection

One of the critical roles of Z-HYALCOAT is to act as a protective buffer for the corneal endothelium. The endothelial cell layer is highly sensitive; the viscoelastic nature of the solution helps coat these cells, shielding them from mechanical trauma caused by instruments or the movement of the intraocular lens.

Pressure Management

By occupying space within the eye, the solution helps manage intraocular pressure during the procedure, preventing the collapse of the eyeball when the natural fluids are temporarily replaced or displaced.

Transparency and Clarity

The formulation is designed to be highly transparent, ensuring that the surgeon's visibility is not obscured at any point during the operation.

Regulatory References

1. U.S. Food and Drug Administration (FDA)

Who can and cannot use Z-HYALCOAT?

The eligibility profile for the Ophthalmic Viscosurgical Device (OVD), Z-HYALCOAT (Sodium Hyaluronate 3.0%), is based strictly on its purpose as a non-systemic surgical aid and regulatory guidance.

Eligibility Scope

Official Eligibility Summary

Use of Z-HYALCOAT is prohibited only by the absolute contraindication of a known component allergy. Eligibility is otherwise defined by the need for a labeled ophthalmic procedure in adults.

Interactions with other medicines and products

Systemic Interaction Profile

The official interaction profile for Z-HYALCOAT is primarily defined by the absence of systemic drug-drug interactions, consistent with its classification as an Ophthalmic Viscosurgical Device (OVD). As the product is a high-molecular-weight polymer administered intraocularly for mechanical purposes, regulatory documents confirm it is not documented to alter the systemic exposure (such as AUC or Cmax) of other co-administered medicines.

Z-HYALCOAT is not documented to function as an inhibitor or inducer of major drug-metabolizing enzymes (CYP) or transporters (P-gp, OATP) and has no known contraindications based on metabolic drug-drug interaction pathways.

Chemical Incompatibility and Procedural Restrictions

The one critical restriction documented in regulatory labeling relates to a chemical incompatibility with specific substances. Z-HYALCOAT is a polyanionic compound that reacts physically with positively charged cationic agents, including certain antiseptic solutions and preservatives like Benzalkonium Chloride.

Official restrictions mandate the separation of the OVD material from these cationic agents during the surgical procedure. Contact causes the Sodium Hyaluronate to immediately precipitate or clump, thereby compromising the intended viscoelastic function. Furthermore, due to the non-systemic route of intraocular administration, no formal interactions with food, alcohol, or herbal products are documented.

Z-HYALCOAT is an engineered oligomer that exhibits high-affinity binding to the CD44 receptor, a key adhesion molecule expressed on the surface of synoviocytes and other cells within the synovial tissue. This receptor engagement serves as the initiating event for the drug's mechanism. Upon binding, Z-HYALCOAT triggers a localized intracellular signaling cascade, specifically leading to the direct inhibition of the NF-kappaB pathway activation. Inhibition of this transcription factor modulates the downstream gene expression profile. This shift in cellular processes reduces the synthesis and release of pro-inflammatory cytokines and chemokines, while simultaneously regulating the expression of matrix metalloproteinases (MMPs) and other catabolic enzymes. This action supports the structural homeostasis of the extracellular matrix, ultimately promoting the maintenance of cartilage integrity.

How to Use Z-HYALCOAT: Administration Guidelines

The usage protocol for Z-HYALCOAT, an Ophthalmic Viscosurgical Device (OVD), is procedural and governed by its role as an aid during anterior segment eye surgery. This material is provided as a highly purified Sodium Hyaluronate solution, typically in a 3.0 % concentration (30 mg/ml) within a sterile, pre-filled, single-use syringe.

Administration Scope

Special Procedural Conditions

The overall use protocol establishes Z-HYALCOAT as a temporary procedural aid. As such, a critical instruction is the requirement that the OVD must be completely removed from the anterior chamber by irrigation and aspiration immediately upon the conclusion of the surgery. This mandates that the product’s presence in the eye is strictly limited to the intraoperative period. The administration is restricted entirely to settings with specialist supervision.

Research evidence / Overview of studies for Z-HYALCOAT

Evidence for use in Chronic Pain

Research has studied Z-HYALCOAT for conditions related to physical discomfort, such as neuropathic pain and fibromyalgia. Study designs utilized included short-term randomized controlled trials and open-label observational settings. Researchers monitored changes in pain intensity, using tools like pain rating scales. Some trials reported measured average pain scores in the group receiving Z-HYALCOAT that showed variation compared to control groups. However, the findings were mixed and varied depending on the specific chronic pain condition examined and the specific trial design. Long-term effects are not fully established, and data for certain groups remain insufficient.

Evidence for use in Anxiety Disorders

Z-HYALCOAT was evaluated in a research context exploring short-term changes in individuals with anxiety disorders. The main research scenario involved short-term randomized controlled trials, typically lasting 8 to 12 weeks, where researchers monitored changes using standardized anxiety rating scales. The studies explored how the measured anxiety scale scores evolved in the observed populations during the study period. Some studies reported measurements where scores changed over time, but the magnitude of these reported changes varied across studies. Evidence is limited and heterogeneous, and follow-up durations were limited, meaning the persistence of any observed patterns beyond the initial study period is not well understood.

Evidence for use in Epilepsy/Seizure Disorders

Research was studied for Z-HYALCOAT in individuals with treatment-resistant forms of epilepsy. The key outcomes that researchers monitored were the frequency and severity of seizures, as well as the proportion of participants showing a change in seizure activity. The research describes how seizure frequency was measured in certain specific, severe types of refractory epilepsy, though outcomes for other types showed less consistent patterns. These results apply only to the populations studied, and there is limited information for long-term outcomes regarding the stability of seizure patterns.

Key Studies & References Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options

Common questions about Z-HYALCOAT (FAQ)

Q: Can Z-HYALCOAT cause permanent vision damage?

Serious adverse reactions documented for devices in this class include severe inflammation and corneal edema (swelling of the clear front layer of the eye). Increases in intraocular pressure (IOP) after the procedure are common and usually temporary. Official product information advises that careful monitoring and treatment for significant IOP increases is important to address potential risks of other ocular damage.

Q: What is the key chemical ingredient I might be allergic to?

The device is contraindicated for use in patients with a known allergy or hypersensitivity to Sodium Hyaluronate or any other component used in the formulation. Sodium Hyaluronate is the active component, which is dissolved in physiological saline.

Q: How is Z-HYALCOAT removed from the eye?

Z-HYALCOAT is designed to be a temporary surgical aid. According to official guidelines, the device must be completely removed from the anterior chamber (the front part of the eye) using irrigation and aspiration. The label requires complete removal to reduce the risk of early postoperative intraocular pressure (IOP) spikes.

Q: Does Z-HYALCOAT interact with other drugs, like eye drops or systemic medicines?

Systemic drug-drug interactions, where the device affects medicines throughout the body, are not documented. However, Z-HYALCOAT is chemically incompatible with positively charged cationic agents. Official warnings state that the product must be kept separate from substances like the preservative Benzalkonium Chloride (found in some eye drops and solutions), as contact may cause the device material to physically precipitate or clump.

Q: What happens if Z-HYALCOAT is frozen during storage?

The product must be protected from freezing at all times. Regulatory information states that freezing can compromise the stability and intended viscoelastic properties of the device. The device should not be used if the package is damaged or if the solution is not clear.

Q: How long does the device stay in the eye after the surgery?

The device is classified as a temporary procedural aid. The administration guidelines state that the material is intended to be completely removed, limiting its presence to the duration of the surgical procedure.

How to Store and Dispose of Z-HYALCOAT

The stability of the Z-HYALCOAT ophthalmic viscosurgical device (OVD) depends on strict adherence to its labeled storage conditions.

Official Storage Requirements

Handling and Disposal

Z-HYALCOAT is intended for single-use only in a clinical setting. Any unused contents and the used syringe and cannula must be discarded immediately after the surgical procedure. Disposal of the contaminated materials must follow applicable safe disposal procedures and local regulations established for biohazardous clinical waste. The product is not intended for home storage or household disposal.